“Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study”, The Lancet, October 2022

RACE is a (completed) phase 3, multicentre, open-label, parallel-group, randomised controlled trial done in 23 French centres of expertise for pulmonary hypertension enrolling treatment-naive patients aged 18–80 years with newly diagnosed, inoperable chronic thromboembolic pulmonary hypertension and pulmonary vascular resistance of more than 320 dyn·s/cm⁵.

A summary of the article is available on The Lancet web page at this link

Citation

Xavier Jaïs, MD, Philippe Brenot, MD, Hélène Bouvaist, MD, Mitja Jevnikar, MD, Matthieu Canuet, MD, Céline Chabanne, MD, Prof Ari Chaouat, MD, Prof Vincent Cottin, MD, Pascal De Groote, MD, Nicolas Favrolt, MD
Delphine Horeau-Langlard, MD, Pascal Magro, MD, Prof Laurent Savale, MD, Grégoire Prévot, MD, Sébastien Renard, MD, Prof Olivier Sitbon, MD, Florence Parent, MD, Romain Trésorier, MD, Cécile Tromeur, MD, Céline Piedvache, MSc, Prof Lamiae Grimaldi, MD, Prof Elie Fadel, MD, Prof David Montani, MD, Prof Marc Humbert, MD, Prof Gérald Simonneau, MD.
Published: August 01, 2022, DOI: https://doi.org/10.1016/S2213-2600(22)00214-4